FIELD: biochemistry.
SUBSTANCE: invention relates to biochemistry. Disclosed are versions of a monoclonal antibody against human CD52. Invention also discloses isolated nucleic acids and recombinant expression vectors, coding an antibody or a light chain or a heavy chain of antibody against human CD52, host cells, as well as method of producing said antibody. Antibodies against human CD52 can be used for therapeutic purposes for treating, for example, an autoimmune disease, cancer, non-Hodgkin lymphoma, multiple sclerosis and chronic lymphocytic leukaemia.
EFFECT: invention increases antibody-dependent cell-mediated cytotoxicity of antibodies against human CD52.
45 cl, 246 dwg, 29 tbl, 70 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODIES AGAINST OX40 AND THEIR USE | 2017 |
|
RU2783314C2 |
| ANTI-ErbB3 ANTIBODIES | 2011 |
|
RU2568051C2 |
| ANTIBODIES AGAINST αβTCR | 2012 |
|
RU2630656C2 |
| ANTIBODY IGG WITH AFFINITY BINDING WITH RESPECT TO ANTIGENIC COMPLEX CD3, RECOMBINANT NUCLEIC ACIDS ENCODING ANTIBODY LIGHT AND HEAVY CHAIN, METHOD FOR PREPARING SYSTEM, METHOD FOR PREPARING ANTIBODY, METHOD FOR TREATMENT OF PATIENT | 1999 |
|
RU2244720C2 |
| ANTIBODIES AGAINST PD-1 AND THEIR USE | 2018 |
|
RU2788616C2 |
| IMMUNOTHERAPEUTIC AGENT COMBINED WITH CD37, AND ITS COMBINATION WITH BIFUNCTIONAL CHEMOTHERAPEUTIC AGENT | 2009 |
|
RU2531754C2 |
| HUMANIZED ANTIBODY TO CD52 | 2012 |
|
RU2605307C2 |
| ANTI-c-Met ANTIBODY | 2009 |
|
RU2560257C2 |
| ANTIBODY AGAINST CLAUDIN 18A2 AND APPLICATION THEREOF | 2017 |
|
RU2793445C2 |
| ANTIBODIES TO H7CR | 2013 |
|
RU2691428C2 |
